I haven't seen another biotech where they have simultaneously been accepted to present at so many elite conferences. With so many deals in radiopharma, while Alan would already be courted by some BPs, more interest and discussions are expected to be happening before, at and after these conferences. Can only imagine Novartis wanting a piece of the TCT pie as they are building a portfolio of all sorts of radiopharma treatments.
SAR Bombesin is targeting a totally unmet need. Our dose expansion at 12GBq could yield more of the 'cancer-free' results that came from 2 cycles of 8GBq. Juicy! This company is too ripe at the moment but the positive news flow combined with soon to be announced (?) new preclinical trials definitely has us at the edge of our seats - a definite first for me.
(I just managed to top up today and I hope we have 12 months to take advantage of the CGT discount, which more and more is looking unlikely.)
AIMO. No advice.
I haven't seen another biotech where they have simultaneously...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.19 |
Change
0.000(0.00%) |
Mkt cap ! $1.616B | |||
| Open | High | Low | Value | Volume |
| $5.19 | $5.25 | $5.12 | $5.293M | 1.018M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 16308 | $5.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.20 | 3909 | 1 |
View Market Depth
| Last trade - 16.10pm 11/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$5.20 |
Change
0.000 ( 0.03 %) |
||||
| Open | High | Low | Volume | ||
| $5.16 | $5.25 | $5.14 | 126843 | ||
| Last updated 15.59pm 11/06/2024 ? | |||||
| CU6 (ASX) Chart |